Back to search results

Endurance Exercise for Obesity and Fat Tissue Health

This study is looking at how endurance exercise affects fat tissue quality and how your body uses insulin in people with obesity. You would participate in endurance exercise training three times a week for about 12 weeks, using either a stationary bike or treadmill. Researchers will take samples of your muscle and fat tissue (biopsies) and measure how your body responds to insulin using a glucose clamp test. They will also use an accelerometer to track your activity. The main goal is to see changes in fat tissue formation (adipogenesis) after 12 weeks. This study is for men and pre-menopausal women aged 18-45 with a BMI between 30.0 and 40.0 kg/m2. The study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 70 participants. It compares endurance exercise training to a control group (no exercise).
What's involved
You would visit the study site three times a week for approximately 12 weeks for 75-minute endurance exercise sessions. You would also undergo muscle and fat biopsies, a glucose clamp test, and wear an accelerometer.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken before and after 12 weeks of the study interventions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06602141

Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise

Recruiting
NAAges 18–45InterventionalTreatment
AdventHealth Translational Research Institute
~70 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:Muscle BiopsyAdipose BiopsyGlucose ClampAccelerometerEndurance ExercisePhysical activity/ dietary habits

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
In vivo adipogenesis
Measured over Before and following 12 weeks of deuterium (2H) labelled water administration and either endurance exercise training or control (no exercise)

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

2 sites across 2 states
Florida1
Louisiana1

Study leadership

  • Lauren Sparks, PhD · PRINCIPAL_INVESTIGATOR · AdventHealth Translational Research Institute
  • Ursula White, PhD · PRINCIPAL_INVESTIGATOR · Pennington Biomedical Research Center

Who to contact

Recruitment Department
[email protected]
407-303-7100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Dose change for any chronic-use drug in the last 3 months;
Cardiovascular: beta blockers and centrally acting anti-hypertensive drugs, anticoagulants, antiarrhythmics, and antiplatelet drugs (other than aspirin ≤100 mg/day);
Psychiatric: chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines (short-acting non-benzodiazepine sedative-hypnotics are allowed), mood stabilizers, antiepileptic drugs, stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs, anti-psychotic drugs;
Pulmonary/Inflammation: chronic oral steroids (inhaled steroids are allowed), burst/taper oral steroids more than once in the last 12 months, B2-agonists (allowed if on stable dose at least 3 months);
Genitourinary: 5-alpha reductase inhibitors, daily phosphodiesterase type 5 inhibitor;
Hormonal: androgenic anabolic steroids, anti-estrogens, anti-androgens, estrogens and/or progestins used for reasons other than birth control, growth hormone, insulin like growth factor-I, growth hormone releasing hormone, any drugs used to treat diabetes mellitus or lower blood glucose, metformin for any indication, any drugs used specifically to induce weight loss, any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy;
Pain/Inflammation: narcotics and narcotic receptor agonists, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, muscle relaxants ≥2 days per week;
Other: chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc.) for any reason, high-potency topical steroids if ≥10% surface area using rule of 9s, continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention, monoclonal antibodies, anti-rejection medications/immune suppressants; 39. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.

What this trial measures

  • In vivo adipogenesisBefore and following 12 weeks of deuterium (2H) labelled water administration and either endurance exercise training or control (no exercise)

    A subcutaneous white adipose tissue biopsy from the abdomen will be collected before and after 12 weeks of deuterium (2H) labelled water administration and either endurance exercise training or control (no exercise). New adipocyte formation will be assessed on frozen isolated 2H2O labelled adipose tissue cells